By Fineline Cube 
Beijing Sun‑Novo Pharmaceutical Research Co., Ltd. today disclosed a strategic capital injection of RMB 15 million into Byterna Therapeutics Ltd., purchasing the company’s newly issued shares for RMB 1.1 million. The transaction will leave Sun‑Novo with an 8.20 % stake in Byterna, underscoring its commitment to expanding the pipeline of in‑vivo CAR‑T cell therapies and nucleic‑acid medicines.
Investment & Strategic Rationale
| Item | Detail |
|---|---|
| Capital Infusion | RMB 15 million (RMB 1.1 million in newly issued shares) |
| Ownership Post‑Deal | Sun‑Novo holds 8.20 % of Byterna’s registered capital |
| Strategic Focus | Strengthen Sun‑Novo’s portfolio in in‑vivo CAR‑T & nucleic‑acid therapeutics |
| Byterna’s Specialty | Circular RNA (circRNA)‑based drug discovery & advancement of CAR‑T therapies for autoimmune & malignant diseases |
Why the Deal Matters
- Pioneering CircRNA Platform – Byterna’s circRNA technology offers a stable, safe, and scalable vector for delivering CAR‑T payloads directly to target tissues.
- Access to New Market Segments – The partnership allows Sun‑Novo to diversify beyond conventional small‑molecule drugs into next‑generation cell‑ and gene‑based therapies.
- Accelerated Clinical Translation – With Byterna’s roadmap to the first clinical‑stage, modified circRNA‑based in‑vivo CAR‑T therapy, both companies can move swiftly from discovery to patients.
Forward‑Looking Statements
The statements contained herein are forward‑looking and are based on current expectations; actual results may differ materially.-Fineline Info & Tech